Skip to content

BBIOBiotechnology: medicines for genetic diseases

BridgeBio Pharma

By

Updated

Not investment advice. Kevin may own this stock. How we value stocks

History
Price
$76.03
Discount category
Close to intrinsic value
Analysts
Bullish
Next earnings
Feb 23 · · estimated
Pick status
Research only

In short

Thesis
The market weighs fast Attruby growth and three near FDA decisions at BridgeBio against its losses and large claims ahead of common stock, and approvals with rising sales through 2027 can lift its value.
Gap
Can close. Three FDA decisions, on November 27, 2026, February 4, 2027 and May 8, 2027, and the Attruby sales of each quarter show whether BridgeBio can reach a steady profit.

Price history

About

BridgeBio Pharma, Inc. (BridgeBio) is based in Palo Alto, California. It develops medicines for genetic diseases. Its product Attruby (acoramidis) treats transthyretin amyloid cardiomyopathy (ATTR-CM). Bayer sells acoramidis as BEYONTTRA in Europe and Japan and pays royalties and milestones.

BridgeBio has three more medicines under FDA Priority Review: BBP-418 for limb-girdle muscular dystrophy type 2I/R9, oral infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1 (ADH1). Total revenues were $353.2 million in Q3 2026, of which US Attruby net product revenue was $253.2 million. The common stock trades on Nasdaq in US dollars. BridgeBio files 10-K and 10-Q reports.

Thesis

BridgeBio still loses money, so its price depends on how fast Attruby sales grow and on whether its three new medicines get approved and sell. US Attruby net product revenue rose to $253.2 million in Q3 2026 from $108.1 million a year before. The loss from operations was $11.6 million in Q3, with a one-time milestone of $75.0 million from Bayer, and $224.7 million for nine months.

Large claims come before the common stock: convertible notes of $2,505 million in principal, deferred royalty obligations of $884.1 million and Series A preferred stock with a liquidation preference of $1,134.4 million. For the price to rise, three things must be true. Attruby must keep taking share from tafamidis in ATTR-CM.

The FDA must approve BBP-418 by November 27, 2026, oral infigratinib by February 4, 2027 and encaleret by May 8, 2027, and the launches must sell. Operating costs must grow slower than revenue, so that BridgeBio earns a steady profit. The three FDA decisions and the Q4 2026 report in February 2027 are the next tests.

Checkpoints

  1. Nov 27, 2026Pending
    FDA decision on BBP-418The FDA approves BBP-418 for limb-girdle muscular dystrophy type 2I/R9 by November 27, 2026, and this passes; a rejection or a delay fails.
  2. Feb 4, 2027Pending
    FDA decision on oral infigratinibThe FDA approves oral infigratinib for achondroplasia by February 4, 2027, and this passes; a rejection or a delay fails.
  3. Feb 23, 2027 · est.Pending
    Q4 2026 resultsUS Attruby net product revenue grows again from the $253.2 million of Q3 2026, and this passes; flat or lower revenue fails.
  4. May 8, 2027Pending
    FDA decision on encaleretThe FDA approves encaleret for ADH1 by May 8, 2027, and this passes; a rejection or a delay fails.

Every passed and failed checkpoint across all picks

Recent events

  • October 29, 2026BridgeBio reported Q3 2026 results. Total revenues were $353.2 million, against $120.7 million a year before, and US Attruby net product revenue was $253.2 million. Revenues included a sales milestone of $75.0 million from Bayer. The loss from operations was $11.6 million. Cash, cash equivalents and marketable securities were $1.5 billion.
  • October 6, 2026The FDA accepted the application for oral infigratinib in achondroplasia with Priority Review. The target action date is February 4, 2027.
  • August 31, 2026BridgeBio announced an agreement with the US government on the prices of medicines. It expects its price commitment for future medicines to exclude medicines approved only for orphan diseases.
Show 5 older events
  • August 13, 2026KKR Genetic Disorder L.P. sold 5,000,000 shares of BridgeBio at $78.00 per share. BridgeBio received no proceeds.
  • July 22, 2026The FDA accepted the application for encaleret in ADH1. The target action date is May 8, 2027.
  • July 1, 2026BridgeBio sold 933,900 shares of Series A convertible preferred stock for $933.9 million to funds of Sixth Street Partners and HealthCare Royalty. The preferred stock accrues dividends at 7.00% a year at first and converts at $137.79 per share.
  • May 27, 2026The FDA accepted the application for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 with Priority Review. The target action date is November 27, 2026.
  • January 21, 2026BridgeBio issued $632.5 million of convertible notes due 2033, with a conversion price of about $110.58 per share.

Latest news and filings

Last earnings
October 29, 2026 (8-K on sec.gov)
Next earnings
Expected about February 23, 2027. The company has not confirmed the date.

Every filing on SEC EDGAR (CIK 1743881)

Risks

  • Large claims come before the common stock. At September 30, 2026, convertible notes were $2,505 million in principal, deferred royalty obligations were $884.1 million and the Series A preferred stock had a liquidation preference of $1,134.4 million.
  • Three FDA decisions are close. The FDA can reject or delay BBP-418, oral infigratinib or encaleret, and an approved medicine can sell less than planned.
  • Attruby competes with other ATTR-CM medicines, such as tafamidis. US price rules, such as most-favored-nation pricing, can lower its net price.
  • The share count can grow. The notes can convert into about 37.8 million shares and the preferred stock into about 6.8 million shares, and options and stock units add about 18.1 million more.
  • Milestone revenue is uneven. The $75.0 million Bayer milestone lifted Q3 2026 revenues, and such payments do not repeat each quarter.

Key statistics

Market cap
$15B
Shares of Oct 22, 2026
EPS (trailing)
-$3.03
12 months to Sep 30, 2026
52-week range
$62.50 – $93.42
To Nov 12, 2026
Beta
0.97
Vs S&P 500, 5 years monthly, to Oct 30, 2026
Average volume
2.7M
3 months, to Nov 12, 2026

Balance sheet

Cash
$1.5B
Debt
$2.5B
Net debt
$966M

Cash against debt

Cash$1.5B
Debt$2.5B

debt covered by cashnet debt $966M

When the debt is due

12 months$550M
Later$2.0B

The last debt is due in 2033.

At September 30, 2026, BridgeBio had cash, cash equivalents and marketable securities of $1,538.9 million. Convertible notes were $2,505 million in principal: $550.0 million of 2.50% notes due March 15, 2027, $747.5 million due 2029, $575.0 million due 2031 and $632.5 million due 2033.

Dividends

BridgeBio Pharma does not pay a dividend.

Source: company filings and market data, read on November 12, 2026.

Questions about BridgeBio Pharma

What does BridgeBio Pharma do?

BridgeBio Pharma, Inc. (BridgeBio) is based in Palo Alto, California. It develops medicines for genetic diseases. Its market cap is $15B at the current price of $76.03.

When does BridgeBio Pharma report earnings next?

This is an estimate: BridgeBio Pharma may report on February 23, 2027. It last reported results on October 29, 2026.

Is BridgeBio Pharma stock below its intrinsic value?

BridgeBio Pharma stock is close to intrinsic value. This is general information, not advice.

What changed recently at BridgeBio Pharma?

The latest update is from October 29, 2026. BridgeBio reported Q3 2026 results.

What are the main risks for BridgeBio Pharma?

Large claims come before the common stock. Three FDA decisions are close. Attruby competes with other ATTR-CM medicines, such as tafamidis.

How much debt and cash does BridgeBio Pharma have?

At September 30, 2026, BridgeBio Pharma had $2.5B of debt and $1.5B of cash.

Does BridgeBio Pharma pay a dividend?

No. BridgeBio Pharma does not pay a dividend.

Valuation against peers

CompanyP/E, last 4 quartersEV/EBITDA, last yearFree cash flow yield, last year10-year average P/E
BBIOBridgeBio Pharman/an/a-3.0%n/a
GILDGilead Sciencesn/an/a4.6%16.2x
BIIBBiogen108.0xn/a5.6%18.2x
JAZZJazz Pharmaceuticals68.1xn/a8.8%20.0x
ELANElanco Animal Healthn/an/a2.2%n/a
Peer median88.1xn/a5.1%n/a
  • Its free cash flow yield is -3.0%, 8.1 points below the peer median of 5.1%.

The peers are the companies on this site most like BBIO. The multiples come from company filings and today's price. There are no analyst forecasts: they all look back. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.

Similar companies

  • GMABGenmabShares: High debt, Regulation and courts
    Intrinsic value
    Far above intrinsic value (AI estimate)
    Gap
    Slow
  • GILDGilead SciencesShares: Regulation and courts, High debt
    Intrinsic value
    Far above intrinsic value
    Gap
    Can close
  • BIIBBiogenShares: High debt, Regulation and courts
    Intrinsic value
    Pricey
    Gap
    Can close
  • JAZZJazz PharmaceuticalsShares: Regulation and courts, High debt
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close
  • ELANElanco Animal HealthShares: High debt, Regulation and courts
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close

Loading your notes…

Read it all? Star BBIO or pass, then go on to the next one.